A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Glufosfamide (Primary) ; Gemcitabine
- Indications Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 12 May 2009 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Actual End Date (Jul 2007) added as reported by ClinicalTrials.gov.